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deficient rods cope, which are larger in 
size than cones and need 100,000,000 
opsins/cell.
The unaltered insiders discussed above 
are altered in other cancers; thus, whether 
abnormal or normal activity of a particular 
gene contributes to tumorigenesis is con-
text dependent. There must also be genes 
that are expressed in one cell, where they 
counter transformation, and are naturally 
off in a neighbor, increasing its suscep-
tibility. Discovering the basal unaltered 
features of different cell types that render 
them more cancer prone will expand the 
repertoire of potential therapies. Several 
labs are already testing MDM2/4 thera-
peutics, and if thyroid hormone is required 
for cancer-promoting activity of THRβ2, 
perturbations in its transport or activation 
may also be helpful.
The cone phenotype of retinoblastoma 
suggests, but does not prove, that the dis-
ease originates from cones. Passengers 
disembarking from a plane wearing winter 
coats imply a chilly origin, but equally could 
signify a frigid destination. Guessing where 
cancer starts from its end-stage appear-
ance is equally ambiguous. If retinoblas-
toma arises from cones, one would expect 
more tumors at the fovea, a cone-rich 
region located within the posterior (cen-
tral) human retina. When newborn children 
with heterozygous loss of RB1 are tracked, 
nascent tumors do appear first at the poste-
rior pole, but not preferentially at the fovea, 
and tumors also arise later in the periphery 
(B. Gallie, personal communication), which 
fits the posterior-anterior developmental 
wave rather than a cone origin. Cones in 
the outer retina synapse with interneurons 
in the inner nuclear layer. Tumors have been 
observed emerging here (Figure 1C), which 
may arise from displaced cones, or vari-
ous interneurons or Müller glia in the inner 
nuclear layer. Retinoblastoma in mice also 
arises in the inner nuclear layer, exploiting 
the intrinsically high resistance of amacrine 
or horizontal neurons to apoptosis (Ajioka 
et al., 2007; Chen et al., 2004; MacPherson 
et al., 2004). Emerging from one ground 
state and converting to another seems 
elaborate, but altering cell type is not oner-
ous (induced pluripotent stem cells are a 
topical example), and “transformation” is 
cancer’s defining feature. Until the early 
response of different human retinal cells 
to RB1 loss and the routes adopted dur-
ing progression are understood, we remain 
(cones or no cones) very much in the dark. 
Wherever it is first employed, the cone 
circuitry is clearly a crucial component in 
retinoblastoma.
Like other breakthroughs in the study of 
retinoblastoma, the latest milestone has 
significance well beyond the eye. Normal 
is not the same as harmless. As genome-
wide sequencing projects continue 
onward toward the goal of uncovering all 
oncogenic mutations in all tumor types, 
the next major step will be to expose their 
hidden accomplices.
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Inactivation of mahogunin, an E3 ubiquitin ligase, causes a spongiform encephalopathy resembling 
prion disease. Chakrabarti and Hegde (2009) now report that prion proteins with aberrant topologies 
inactivate mahogunin, providing a plausible explanation for certain aspects of prion pathology.Transmissible spongiform encephalopa-
thies, or prion diseases, are neurode-
generative conditions caused by prions, 
atypical infectious agents consisting of 994 Cell 137, June 12, 2009 ©2009 Elsevier PrPSc, a misfolded and aggregated form 
of the cellular prion protein (PrPC). PrPC 
is a cell-surface GPI-anchored glycopro-
tein that is normally produced in abun-Inc.dance in brain, muscle, and the immune 
system (Aguzzi et al., 2008). Although we 
have a robust model of how prions repli-
cate, we still do not understand how and 
why the central nervous system (CNS) 
is preferentially damaged. The relatively 
small amounts of PrPSc needed to dis-
rupt CNS function suggest that prions 
target highly specific weak points in the 
system.
The key features of nearly all prion dis-
eases are transmissibility and a foamy 
pattern (spongiosis) of brain tissue that 
is visible on histological sections. Spon-
giosis is due primarily to intraneuronal 
vacuoles containing membrane frag-
ments and, sometimes, degenerating 
organelles, but the etiology of this highly 
characteristic pathology is unclear. Much 
excitement surrounded the discovery 
that mutations in an E3 ubiquitin ligase 
called mahogunin cause similar spongi-
form changes in the CNS of “mahog-
anoid” mice (He et al., 2003). This sup-
ported the notion that disorders of the 
proteasome degradation pathway may 
be involved in the toxicity of PrPSc. How-
ever, recombinant prion protein does not 
undergo ubiquitination by mahogunin, 
and the potential link between mahog-
unin and the pathogenic prion protein 
has remained untested.
In this issue, Chakrabarti and Hegde 
(2009) report a physical interaction 
between mahogunin and PrPC that 
has acquired improper topologies. 
Although the bulk of PrPC is turned over 
via the endolysosomal system, some is 
degraded by the proteasome (Ma et al., 
2002 and references therein), which is 
the main degradation system for cyto-
solic proteins (Figure 1). A minor patho-
genic form of PrP called cyPrP, which 
lacks a secretory signal peptide and is 
constitutively released into the cytosol, 
is extremely neurotoxic to cerebellar 
neurons of transgenic mice (Ma et al., 
2002). The neurotoxicity of cyPrP may 
be more widespread than initially appre-
ciated as transgenic mice with inducible 
forebrain-restricted expression of cyPrP 
show behavioral and neuropathological 
phenotypes (Wang et al., 2009).
In previous work, Hegde and col-
leagues noted that cyPrP accumulates in 
the cytosol due to its inefficient import 
into the endoplasmic reticulum (ER) 
attributable to a weak secretory sig-
nal sequence. Indeed, transgenic mice 
expressing PrP with a very inefficient 
secretory signal exhibit a mild neurode-
generative phenotype (Rane et al., 2008), supporting the view that the cytosolic 
accumulation of PrPC can be neurotoxic. 
However, there has been much debate 
as to whether the cytosolic accumula-
tion pathway is relevant to the toxicity of 
naturally occurring prion infections. To 
some extent, this discussion reflects the 
fact that it is extremely difficult to detect 
cyPrP and hence to design an experi-
ment that would disprove its relevance 
to prion diseases.
In their new work, Chakrabarti and 
Hegde (2009) discover a functional 
interaction between cyPrP and mahog-
unin, leading to an exciting new model 
for how mislocalized prion proteins can 
lead to neuronal damage and loss. Given 
that naked cyPrP is unstable unless the 
proteasome is inhibited pharmacologi-
cally, the authors began by developing 
a GFP-tagged version of cyPrP that has 
greatly enhanced stability. Coexpression 
of tagged mahogunin led to a tight asso-
ciation with aggregated cyPrP. Mahog-
unin did not aggregate with a fragment of 
huntingtin, a protein involved in a differ-
ent type of neurodegenerative disease, 
suggesting that mahogunin does not 
bind generically to all pathogenic protein 
aggregates. Another putative neurotoxic 
PrP species, CtmPrP, displays an atypi-
cal transmembrane topology and is also 
figure 1. the cellular fates of PrP
In the default pathway (black arrows), the mRNA encoding the normal cellular version of the prion protein 
(PrPC; blue) is translated by ribosomes docked at the ER and then is imported cotranslationally into the 
ER lumen. In the ER, a GPI anchor (orange oval) is attached to the C terminus of PrPC (purple), which 
will tether the protein to the plasma membrane. However, some fraction of PrP misfolds within the ER 
and is then retrotranslocated to the cytosol (cyPrP) to be degraded by the proteasome (green arrows). 
PrP can also end up in the cytosol via the pre-emptive quality control pathway in which ER stress leads 
to a lack of cotranslational import, and secretory proteins are translated and degraded in the cytosol 
(green arrows). During cotranslational import, a small fraction of PrP (CtmPrP) adopts a transmembrane 
conformation with the C terminus in the ER lumen and the N terminus facing the cytosol (gray arrows). 
CtmPrP may be retained within either the ER or the Golgi. Cytosolic PrP (cyPrP) and CtmPrP bind tightly to 
mahogunin (green), an E3 ubiquitin ligase that has been implicated in mediating spongiform pathology 
in the mouse brain.Cell 137, June 12, 2009 ©2009 Elsevier Inc. 995
associated with mahogunin. Lysosomal 
morphology was altered in the same way 
by loss of mahogunin and by cyPrP, sug-
gesting a connection between these two 
proteins. As no substrates of mahog-
unin are known, the authors relied on 
lysosomal morphology as a surrogate of 
mahogunin function. Finally, the authors 
observed loss of mahogunin immunore-
activity and altered lysosomal morphol-
ogy in the brains of mice expressing a 
mutant form of PrP that favors produc-
tion of CtmPrP.
The finding of “bilaminar” spongiosis 
(a pattern of vacuolation that affects two 
discontinuous cortical layers) in human 
brain specimens rings alarm bells with 
any neuropathologist, as it is a harbinger 
of the prototypic prion disease of humans, 
Creutzfeldt-Jakob disease. The new 
study is tantalizing as it suggests that in 
order to decipher the molecular basis of 
prion toxicity we may need to enumerate 
and functionally assess the substrates of 
mahogunin. However, it will be crucial to 
assess whether mahogunin plays a role 
in mediating neurodegeneration in natu-
rally occurring prion diseases such as 
Creutzfeldt-Jakob disease and in experi-
mental models of prion infection such as 
transmission to mice of Rocky Mountain 
Laboratory (RML) scrapie prions.
Although it was the spongiosis in 
mahoganoid mice that flagged the prion-
mahogunin connection, the spongiosis 
phenotype raises some tough questions. 
Given that mahoganoid mice develop 
spongiosis and that both cyPrP and 
CtmPrP appear to sequester mahogunin, 
it would be gratifying to observe spon-
giosis in mice overproducing cyPrP and 
CtmPrP. However, although neither mouse 
strain is healthy, spongiform changes 
in brain tissue are not prominent (Ma 
et al., 2002; Rane et al., 2008; Stewart 
and Harris, 2005). Conversely, spongio-
sis is a hallmark of prion infections, yet 
the extent to which typical prion infec-
tions lead to the generation of cyPrP or 
CtmPrP is unclear, and the effect of prion 
infections on the cellular bioavailability 
of mahogunin has not been investigated. 
So might spongiosis be a “red-herring” 
phenotypic similarity in mahogunin-defi-
cient and prion-infected mice? Investi-
gating this issue will be important given 
that PrP oligomers can interfere directly 
with the proteolytic activity of the pro-996 Cell 137, June 12, 2009 ©2009 Elsevier teasome (Kristiansen et al., 2007), sug-
gesting that there are mahogunin-inde-
pendent pathways of PrPSc toxicity. Also, 
cyPrP interacts with the hydrophobic 
core of membranes implying that it could 
subvert the function of synaptic vesicles 
(Wang et al., 2006).
Another poorly understood aspect of 
prion toxicity is the role of PrPC in cellular 
damage. We know that PrPC is generally 
required for PrPSc to become neurotoxic 
(Brandner et al., 1996). Furthermore, in 
a transgenic mouse expressing a neu-
rotoxic PrP mutant (3AV) with enhanced 
transmembrane topology, coexpression 
of wild-type PrPC contributes to disease 
progression (Stewart and Harris, 2005). 
However, the neurotoxicity of several 
other mutant forms of PrP is antago-
nized effectively by wild-type PrPC. Cur-
rently, there is no convincing theoretical 
framework (including the one sketched 
by Chakrabarti and Hegde) that can rec-
oncile these observations.
So how might the results of Chakrabarti 
and Hegde instruct our understanding of 
neurotoxicity in prion infections? As the 
authors note, there is an increase in ER 
stress markers during prion infection, 
suggesting a vicious circle: misfolded 
PrP generated during prion infection 
may escape from the ER and enter the 
cytosol via a pre-emptive quality control 
pathway described in previous work by 
Hegde and colleagues. This may lead to 
mahogunin inactivation and other untow-
ard events including lipid membrane dis-
ruption and proteasome inhibition, which 
may favor the accumulation of cyPrP and 
prion pathogenesis.
Two key experiments are needed to 
directly test the relevance of the mahog-
unin-cyPrP connection to prion diseases. 
First, if cyPrP is a significant contributor 
to pathogenesis in the infectious forms 
of prion disease, one might expect prion 
infection to be synergistic with cyPrP. 
Hence, mice expressing cyPrP should 
experience aggravated pathogenesis 
after prion infection. However, transgenic 
cyPrP expression shortened the latency 
of disease by only ~15 days in mice 
infected with the RML prion strain (which 
is marginal at best) and not at all with a 
different strain, 22L (W. Jackson, A.D.S., 
and S. Lindquist, unpublished data). Sec-
ond, if prion toxicity is mediated primarily 
by mahogunin, one might expect mahog-Inc.anoid mice (which are not healthy yet live 
long enough for the purpose of this exper-
iment) to become paradoxically resistant 
to prion infection. However, the presence 
of the mahoganoid mutation did not mod-
ulate the progress of RML prion infection 
(G. Carlson and G. Barsh, personal com-
munication). These unpublished results 
suggest that the mahogunin-cyPrP con-
nection may be less crucial for bone fide 
prion infection, or that mahogunin deple-
tion might be compensated for by other 
mechanisms. Conversely, certain familial 
forms of human prion disease are asso-
ciated with only small amounts of PrPSc 
but with increased amounts of CtmPrP 
and are more likely to fit the mechanism 
described by Chakrabarti and Hegde. In 
the long run, small molecules that target 
the mahogunin-cyPrP interaction may 
provide plausible therapeutic leads for 
treating the unfortunate families afflicted 
with these hereditary prion diseases.
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